Allovir, INC Form 4 insider transactions

Laurie Keating, a Director of Allovir, Inc., received 18,000 shares of common stock on August 1, 2026.

Liisa Ann Bayko, Chief Financial Officer of Allovir, Inc., received 220,000 shares of common stock on July 20, 2026.

Director Morana Jovan-Embiricos was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Director Napoleone Ferrara was granted 9,000 stock options in Kalaris Therapeutics, Inc. on June 3, 2026.

Director David Hallal was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Director Srinivas Akkaraju was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Michael Dybbs was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of standard equity compensation.

Director Anthony P. Adamis was granted 9,000 stock options in Kalaris Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Leone D. Patterson was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of a standard equity incentive.

Srinivas Akkaraju and affiliated Samsara BioCapital entities reported internal share transfers and a private purchase of Kalaris Therapeutics stock.

Kalaris Therapeutics' Chief Medical Officer, Matthew Feinsod, was granted 135,000 stock options with a $6.81 exercise price.

Kalaris Therapeutics Director Srinivas Akkaraju, through Samsara Opportunity Fund, L.P., plans to acquire 1.5 million shares of common stock for $15 million on December 22, 2025.

Kalaris Therapeutics' Chief Financial Officer, Matthew Gall, was granted 235,000 stock options with an exercise price of $4.99, vesting over four years.

Srinivas Akkaraju, a director and 10% owner of Kalaris Therapeutics, acquired 18,000 stock options on April 10, 2025.

Morana Jovan-Embiricos, a director at Kalaris Therapeutics, acquired stock options for 18,000 shares at an exercise price of $7.31 on April 10, 2025.

Director Samir Chandrakant Patel acquired stock options for 18,000 shares of Kalaris Therapeutics, Inc.

Director Michael Dybbs of Kalaris Therapeutics acquired 18,000 stock options on April 10, 2025, exercisable at $7.31, vesting over three years.

Brett R. Hagen, Chief Accounting Officer of Kalaris Therapeutics, Inc., reports the acquisition of stock options.

Director Ferrara Napoleone reports acquisition of 18,000 stock options in Kalaris Therapeutics, Inc.

Andrew Oxtoby, CEO of Kalaris Therapeutics, reports the acquisition of stock options.

Anthony P. Adamis, a director of Kalaris Therapeutics, Inc., was granted stock options to purchase 18,000 shares of common stock.

Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics, reports the acquisition of stock options.

Director Leone D Patterson acquired 18,000 stock options in Kalaris Therapeutics, Inc. on April 10, 2025, according to a Form 4 filing.

Director David Hallal acquired stock options for 18,000 shares of Kalaris Therapeutics, Inc. (KLRS) on April 10, 2025.

Brett Hagen, Chief Accounting Officer of Kalaris Therapeutics, sold 907 shares of common stock on March 26, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Director Napoleone Ferrara reports acquisition of Kalaris Therapeutics shares following the completion of a merger.

Director Samir Chandrakant Patel reports acquisition of Kalaris Therapeutics shares and options following the merger with Kalaris Tx, Inc.

Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics, reports acquisition of shares and options following the merger with Kalaris Tx, Inc.

Andrew Oxtoby, a director and officer of Kalaris Therapeutics, acquired stock options as a result of the merger with Kalaris Tx, Inc.

Director Srinivas Akkaraju reports acquiring 11,444,503 shares of Kalaris Therapeutics following the merger with Kalaris Tx, Inc.